The Israeli Prime Minister's office issued the statement in response to what it referred to as a 'completely false' local television report about US pressure on Israel
world1 week ago
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial.
The Phase I trial, which had 72 participants, was designed to assess the safety and tolerability of the pill, as is common in the earliest stage of clinical trials. People enrolled in the trial were either healthy, non-obese volunteers or people with type 2 diabetes.
AstraZeneca shares briefly rose as much as 2.9 per cent to a session high after the data release, before paring some gains. At 15.30 GMT they were up 0.7 per cent.
Stay up to date with the latest news. Follow KT on WhatsApp Channels.
The results from the trial gave AstraZeneca confidence to progress the drug into Phase II clinical trials, Sharon Barr, the company's executive vice president of biopharmaceuticals R&D, told a media briefing.
One of those trials of the drug, called AZD5004, will focus on reduction in body weight on average in obese and overweight participants and is expected to be completed by the end of 2025, Barr said.
When AstraZeneca announced it had licensed the experimental, once-daily obesity pill from Eccogene a year ago for up to $2 billion, it said it believed the treatment could cause fewer side effects than current injectable treatments such Eli Lilly's Zepbound and Novo Nordisk's Wegovy.
AstraZeneca CEO Pascal Soriot acknowledged when the company announced the Eccogene deal in November 2023 that his company was "a few years behind" the roaring success of Novo Nordisk and Eli Lilly who were first to market with highly effective obesity drugs.
Barr also said data from a separate early-stage trial of 14 patients over 28 days showed that the AZD5004 pill can be taken with or without food, with no need for fasting before taking.
US biotech company Viking Therapeutics on Monday released results from an early-stage trial of its own oral obesity treatment that analysts said compared favourably to some rivals in development, leading its shares to climb 9%.
ALSO READ:
The Israeli Prime Minister's office issued the statement in response to what it referred to as a 'completely false' local television report about US pressure on Israel
world1 week ago
Israeli President Isaac Herzog termed the United States as a 'true ally'
world1 week ago
'All acts of escalation are condemnable and must stop', said the spokesman for the Secretary-General
world1 week ago
Indian agencies have uncovered a network that sold fake tickets or charged exorbitant prices for legitimate ones for both concerts
world1 week ago
Saturday's attack was one of the deadliest attacks in the area in recent months
world1 week ago
Satellite data from Brazil's space research agency Inpe showed that Bolivia had 70,628 fire hot-spots up until September 22
world1 week ago
According to airport authorities, flight operations will be halted starting 6:00 PM on Thursday
world1 week ago
Airport operations are currently impacted, and passengers should not come to the airport at this time, the spokesperson said
world1 week ago